ZEVRA THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
| ITEM 15. | EXHIBITS AND FINANCIAL STATEMENT SCHEDULES |
|---|
(a) The following documents are filed as part of this report:
(1) Index list to Financial Statements:
| Page | |
|---|---|
| Report of EY US LLP (PCAOB ID:42) | |
| Consolidated Balance Sheets as of December 31, 2023, and 2022 | 107 |
| Consolidated Statements of Operations for the years ended December 31, 2023, and 2022 | 108 |
| Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, 2023, and 2022 | 108 |
| Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the years ended December 31, 2023, and 2022 | 110 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2023, and 2022 | 111 |
| Notes to Consolidated Financial Statements | 112 |
(2)Financial Statement Schedules
All other schedules are omitted because they are not required or the required information is included in the financial statements or notes thereto.
(3)Exhibits
The exhibits listed in the accompanying Exhibit Index are filed orincorporated by reference as part of this report.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.